Inflammatory & Immunological Biomarkers
The Biomarker Summit 2018, to be held on March 21-23, 2018 in San Diego, CA at the Hilton San Diego Resort & Spa, is a meeting place for leaders in the field to discuss the issues and challenges scientists and researchers face in all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization.
Topics to be covered:
A wide variety of important topics will be covered including biomarker identification, validation, and translation strategies, bioinformatics and systems biology approaches to personalized medicine, big data analytics and management, regulatory and reimbursement trends, companion diagnostics development, and much more. Through scientific presentations, case studies and panel discussions, these areas will be addressed in an intimate and highly interactive environment with perspectives from industry, academia and the public sector.
Assembling leading scientists, researchers, decision-makers and other players across the industry spectrum, the Summit provides a unique opportunity to gain the latest biomarker developments in four major therapeutic areas, formally organized in the following tracks:
- Plenary Keynote Session
- Big Data Analytics & Bioinformatics for Biomarkers Development
- Emerging Technologies in Biomarker Development
- Overcoming Challenges of Clinical Validation & Translation
- Panel Discussion: Companion Diagnostics Development & Partnering Strategies
- Overcoming Commercialization Challenges in Biomarker Development
- Circulating Tumor Cells & Microvesicles
- Liquid Biopsy: Circulating DNA & MicroRNA
- Immuno-oncology Biomarkers
- Novel Technologies in Oncology Biomarkers
- CSF & Blood Based Biomarker Approaches
- Monitoring Progression in Neurodegenerative Disorders
- Novel Technologies in Neurological Biomarkers
- Biomarkers of Early Progressive Inflammatory & Immunological Diseases
- Biomarkers & Surrogate Endpoints for Clinical Trials in Inflammatory Diseases
- Microbiomes in Immune Modulation & Inflammatory Diseases
- Inflammatory Biomarkers in Respiratory Diseases
The 2018 Advisory Committee
|ADVISORY BOARD MEMBERS|
|Kian Kani, University of Southern California|
|Samuil Umansky, DiamiR|
|Bruce McManus, PROOF Centre of Excellence|
|Dobrin Nedelkov, Arizona State University|
|Yong Zhou, Institute for Systems Biology|
|Kendall Jensen, Translational Genomics Research Institute|
|Xuemei Zhao, Merck|
|Chan Whiting, Aduro Biotech|
|Mark Frasier, Michael J. Fox Foundation|
|Stephen Johnston, Biodesign Institute, Arizona State University|
|Roland Staal, Lundbeck Research USA|
|Parag Mallick, Stanford University|
|Carrie Brodmerkel, Janssen R&D|
|Daniel Chelsky, Caprion Proteomics U|
|Laszlo Takacs, BioSystems International; University of Maryland|
|Sandip Patel, University of California San Diego|
|Chinnappa Kodira, GE Global Research Center|
|Charles Glaus , Amgen|
|Stephen Pennington, University College Dublin|
|Jamie (David) Haddon, Genetech|
|Anuraag Shrivastav, University of Winnipeg|
|Zhengyan Kan, Pfizer|
|Andrew Jay, Siemens|
|John Mayfield, Foundation Medicine|
|Pierluigi Mauri, CNR, Institute for Biomedical Tecnologies (ITB-CNR)|
|Nawin Mishra, University of South Carolina|
|Anuradha Guggilam, Publicis Healthcare Communications group Ltd.|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
The 2018 sponsorship is currently in process.
Please come back and visit this page for updates.
BELOW ARE THE SPONSORS FROM 2017.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Myriad RBM, Inc. is the world’s leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on its Multi-Analyte Profiling (MAP) technology platform. This platform provides pre-clinical and clinical researchers with reproducible and quantitative data for a few or hundreds of proteins in a cost-effective manner.
SomaLogic measure 1,310 proteins simultaneously from 65 µL of sample with high sensitivity, specificity and reproducibility. We enable biomarker discovery, better understanding of pathways, target identification, target validation and understanding of off-target effects. We can scale our technology from a large plex (1,310 proteins), to individual analytes, and to panels.
Sengenics is a immuno-diagnostics and therapeutics biotechnology company. Our core focus is leveraging our core patented Immunome technology for discovering antibody-based therapeutics and diagnostic signatures for immune system disorders. Sengenics owns the set of patents for both the fundamental underlying technology as well as commercialisation and joint IP rights for discoveries and applications made with the Immunome platform.
Zimmer & Peacock is the world leader in electrochemical Biosensor design, development, manufacturing and troubleshooting. We partner with you on all aspects of in vitro POC diagnostic devices and sensors. We specialize in translating biomarkers into point of care devices.
Cofactor is leading the charge on moving RNA-seq out of discovery and into diagnostics. Working with the largest life-science and pharmaceutical companies, we’ve developed streamlined and scalable protocols to interrogate RNA. By standardizing RUO RNA-seq products, and developing validated CAP/CLIA assays, we’re trusted partners in advancing precision medicine.
Using novel epigenetic technology, Epiontis provides precise and reproducible immunomonitoring services for clinical trials. The epigenetic PCR tests are based on in-house developed and IP protected markers specific for immune cell types (Treg, Th17, overall Tcells, etc.). Frozen whole blood or tissue can be used, permitting easy storage and logistics.